Abstract
Osimertinib has robust efficacy and is the standard first-line treatment for advanced EGFR-mutant non-small cell lung cancer (NSCLC). The combination of osimertinib with reprotrectinib inhibited Src/FAC/Janus kinase 2 (JAK2) in EGFR-mutant cell lines and abrogated STAT3 and YAP1 signaling with tumor growth inhibition in vitro and in vivo. There was no substantial toxicity in nude mice models. Based on this evidence and repotrectinib's unique inhibition affinity for Src, FAC and JAK2, we designed the current trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
